Trending

ALL

Pfizer objects to NICE methods in leukaemia drug rejection

Pfizer objects to NICE methods in leukaemia drug rejection

NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the

X

Pfizer objects to NICE methods in leukaemia drug rejection

https://pharmaphorum.com/news/pfizer-questions-nice-methods-besponsa/

Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts

Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts

Antibody-drug conjugate with FDA gets six-month review.

X

Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts

https://pharmaphorum.com/news/pfizer-files-leukaemia-antibody-us/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com